BERKELEY, Calif.--Neomorphic Software has closed a deal with SyStemix, a Novartis company. Neomorphic's hidden-Markov-model-based technology will be used to find novel genes in SyStemix's proprietary sequences that are unable to be classified using existing sequence analysis tools. Martin Reese, Neomorphic's chief scientific officer, said the deal would give Neomorphic "the opportunity to work closely with geneticists to verify and optimize this technology towards the discovery of new genes."
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.